SCHEMBL5451443

SCHEMBL5451443

NC(=O)c1c(NC(=O)Nc2ccc(F)c(Cl)c2)sc2c1CCC1(C2)OCCO1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.51
KMT2A Q03164 6/20 0.51
LMNA P02545 3/20 0.51
MAPT P10636 3/20 0.51
HTT P42858 2/20 0.51
KDM4E B2RXH2 1/20 0.51
USP2 O75604 1/20 0.51
ATM Q13315 1/20 0.51
KCNH2 Q12809 10/20 0.49
PTPN1 P18031 1/20 0.48
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
EPHB4 P54760 1/20 0.45
SLC2A1 P11166 1/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
CA2 P00918 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447449 0.88 KMT2A (0.53) MEN1KMT2AMAPTKDM4EKCNH2
SCHEMBL5459253 0.84 PTPN1 (0.52) MEN1KMT2ALMNAMAPTHTT
SCHEMBL5448343 0.83 MEN1 (0.63) MEN1KMT2ALMNAMAPTKCNH2
SCHEMBL5467916 0.83 FLT3 (0.52) MEN1KMT2ALMNAMAPTHTT
SCHEMBL5455882 0.83 PTPN1 (0.49) MEN1KMT2ALMNAMAPTHTT
SCHEMBL5453060 0.83 CFTR (0.54) MEN1KMT2ALMNAMAPTHTT
SCHEMBL5460583 0.83 FLT3 (0.53) MEN1KMT2ALMNAMAPTHTT
SCHEMBL5446288 0.82 MAPT (0.59) MEN1KMT2ALMNAMAPTHTT
SCHEMBL5451995 0.81 FLT3 (0.51) MEN1KMT2AMAPTKCNH2PTPN1
SCHEMBL5451290 0.81 PTPN1 (0.47) MEN1KMT2ALMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MEN1 2891/4885KMT2A 4785/4885LMNA 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.